 |
The UK MS Society is ‘bitterly disappointed’ after the Scottish Medicines Consortium (SMC) advised health professionals not to prescribe Tysabri – the only drug licensed for multiple sclerosis (MS) that has shown significant promise in slowing the progression of disability.
To read more, please click on the link below.
Source: UK MS Society
Weblink: click here
|
